Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Prognostic factors in pediatric acute myeloid leukemia.

Literature DB >> 20652454

Prognostic factors in pediatric acute myeloid leukemia.

Mohamed Radhi¹, Soheil Meshinchi, Alan Gamis.

Abstract

Acute myeloid leukemia (AML), a heterogeneous group of diseases with variable responses to the same therapy, comprises nearly a quarter of childhood acute leukemias. Although historically very few prognostic markers have been incorporated into therapeutic decision making in AML, recent advances in technology have enabled identification of numerous factors associated with disease outcome. This review provides a detailed analysis of most clinically relevant factors associated with disease outcome in childhood AML.

Entities: Disease

Mesh：

Substances：
Biomarkers, Tumor

Year: 2010 PMID： 20652454 DOI： 10.1007/s11899-010-0060-z

Source DB: PubMed Journal: Curr Hematol Malig Rep ISSN： 1558-8211 Impact factor: 3.952

46 in total

1. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.

Authors: Guido Marcucci; Krzysztof Mrózek; Amy S Ruppert; Kati Maharry; Jonathan E Kolitz; Joseph O Moore; Robert J Mayer; Mark J Pettenati; Bayard L Powell; Colin G Edwards; Lisa J Sterling; James W Vardiman; Charles A Schiffer; Andrew J Carroll; Richard A Larson; Clara D Bloomfield
Journal: J Clin Oncol Date: 2005-08-20 Impact factor: 44.544

Review 2. Prognostic factors in acute myeloid leukemia.

Authors: Irit Avivi; Jacob M Rowe
Journal: Curr Opin Hematol Date: 2005-01 Impact factor: 3.284

3. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.

Authors: Ulrike Bacher; Claudia Haferlach; Wolfgang Kern; Torsten Haferlach; Susanne Schnittger
Journal: Blood Date: 2007-10-26 Impact factor: 22.113

4. Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia.

Authors: S M Davies; L L Robison; J D Buckley; T Tjoa; W G Woods; G A Radloff; J A Ross; J P Perentesis
Journal: J Clin Oncol Date: 2001-03-01 Impact factor: 44.544

5. Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia working party.

Authors: J M Chessells; C J Harrison; H Kempski; D K H Webb; K Wheatley; I M Hann; R F Stevens; G Harrison; B E Gibson
Journal: Leukemia Date: 2002-05 Impact factor: 11.528

6. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.

Authors: Peter Paschka; Guido Marcucci; Amy S Ruppert; Krzysztof Mrózek; Hankui Chen; Rick A Kittles; Tamara Vukosavljevic; Danilo Perrotti; James W Vardiman; Andrew J Carroll; Jonathan E Kolitz; Richard A Larson; Clara D Bloomfield
Journal: J Clin Oncol Date: 2006-08-20 Impact factor: 44.544

7. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study.

Authors: Roberto Cairoli; Alessandro Beghini; Giovanni Grillo; Gianpaolo Nadali; Francesca Elice; Carla Barbara Ripamonti; Patrizia Colapietro; Michele Nichelatti; Laura Pezzetti; Monia Lunghi; Antonio Cuneo; Assunta Viola; Felicetto Ferrara; Mario Lazzarino; Francesco Rodeghiero; Giovanni Pizzolo; Lidia Larizza; Enrica Morra
Journal: Blood Date: 2005-12-29 Impact factor: 22.113

8. Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group.

Authors: Richard Aplenc; Todd A Alonzo; Robert B Gerbing; Franklin O Smith; Soheil Meshinchi; Julie A Ross; John Perentesis; William G Woods; Beverly J Lange; Stella M Davies
Journal: Blood Date: 2006-03-14 Impact factor: 22.113

9. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group.

Authors: Verena Ingeborg Gaidzik; Richard Friedrich Schlenk; Simone Moschny; Annegret Becker; Lars Bullinger; Andrea Corbacioglu; Jürgen Krauter; Brigitte Schlegelberger; Arnold Ganser; Hartmut Döhner; Konstanze Döhner
Journal: Blood Date: 2009-02-12 Impact factor: 22.113

10. MRC trials in childhood acute myeloid leukaemia.

Authors: I M Hann; D K W Webb; B E S Gibson; C J Harrison
Journal: Ann Hematol Date: 2004 Impact factor: 3.673

16 in total

1. Lessons learned from the investigational device exemption review of Children's Oncology Group trial AAML1031.

Authors: Soheil Meshinchi; Stephen P Hunger; Richard Aplenc; Peter C Adamson; J Milburn Jessup
Journal: Clin Cancer Res Date: 2012-03-15 Impact factor: 12.531

Review 2. Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia.

Authors: Kelly Faulk; Lia Gore; Todd Cooper
Journal: Paediatr Drugs Date: 2014-06 Impact factor: 3.022

3. Immunologic consequences of chemotherapy for acute myeloid leukemia.

Authors: Anne Reilly; Leslie S Kersun; Eline Luning Prak; Jean Boyer; Kenyetta McDonald; Abbas F Jawad; Kathleen E Sullivan
Journal: J Pediatr Hematol Oncol Date: 2013-01 Impact factor: 1.289

4. Overexpression of IL-3Rα on CD34+CD38- stem cells defines leukemia-initiating cells in Fanconi anemia AML.

Authors: Wei Du; Xu-E Li; Jared Sipple; Qishen Pang
Journal: Blood Date: 2011-02-17 Impact factor: 22.113

5. Survival differences in childhood and young adult acute myeloid leukemia: A cross-national study using US and England data.

Authors: Sherlly Xie; Md Jobayer Hossain
Journal: Cancer Epidemiol Date: 2018-03-16 Impact factor: 2.984

6. Detection of acquired hemoglobinopathy in children with hematological malignancies at disease onset: results form a national referral centre.

Authors: Despoina N Maritsi; Helen V Kosmidis; Varvara Douna; Joanne Traeger-Synodinos; Maria N Tsolia; Lydia Kossiva
Journal: Int J Hematol Date: 2013-10-05 Impact factor: 2.490